title: [DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in France].
abstract: In this study, we used a prevalent cross-sectional sample of French hemodialysis patients from Dialysis Outcomes and Practice Patterns Study (DOPPS) 2 (2002-2004) to determine the percentage of patients whose values failed to meet targets in six different areas of hemodialysis practice (dialysis dose, anemia, serum phosphorus (PO(4)), serum calcium (Ca), serum albumin and catheter use for vascular access). Cox survival models, with adjustments for patient characteristics, were used for these analyses to estimate mortality hazard ratios (HR). Based on the mortality HR, the fraction of patients outside each target and the total HD population in France, we estimated the number of patient life years that could potentially be gained if every chronic, in-center hemodialysis patient in France who is currently outside of the specified target was able to achieve it. The proportion of patients failing to meet one of the six practice targets in France varied from 15% (dialysis dose) to 75% (albumin) while the percentage of patients complying with all six targets was restricted to 1.2%. The relative risk of mortality (RR) associated with being outside these targets varied from 1.12 to 1.46. Based on these two measures the life-years survival was estimated. The projected number of patients and life years potentially gained from adherence to the six targets was estimated close to 10,600 years-patient. In conclusion, this study suggests large opportunities to improve hemodialysis patient care in France still exist. Compliance with two major practice targets, such as albumin and restriction of catheter use will save highly significant life years of hemodialysis patient. Implementing and strict adherence to national and international guidelines should serve as a basic inspiration for continual improvement of hemodialysis patient care.
authors.affiliation: Néphrologie, Dialyse et Soins Intensifs, Hôpital Lapeyronie, CHRU de Montpellier, Montpellier Cedex 05, France. b-canaud@chu-montpellier.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Canaud
authors.forename: Christian
authors.initials: C
authors.lastname: Combe
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Bragg-Gresham
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Eichleay
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Pisoni
authors.forename: Friedrich K
authors.initials: FK
authors.lastname: Port
mesh_terms: D003430:Cross-Sectional Studies; D005602:France; D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D019057:Quality-Adjusted Life Years; D006435:Renal Dialysis / Q000592:standards*; D012709:Serum Albumin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D012709:Serum Albumin